

Food and Drug Administration
Center for Food Safety and Applied Nutrition
Office of Special Nutritionals

ARMS#

12927



0 - FRONT

MEDWATCH

THE FDA MEDICAL PRODUCTS REPORTING PROGRAM

For VOLUNTARY report
by health professionals of
events and product prob

CFSAN

Page of

83864


12927

Individual Safety Report



3082702-5-00

A. Patient information

1. Patient identifier  In confidence	2. Age at time of event: <u>51</u> or Date of birth:	3. Sex <input checked="" type="checkbox"/> female <input type="checkbox"/> male	4. Weight ____ lbs or <u>63.9</u> kgs
--	--	---	--

B. Adverse event or product problem

1. <input checked="" type="checkbox"/> Adverse event and/or <input type="checkbox"/> Product problem (e.g., defects/malfunctions)	
2. Outcomes attributed to adverse event (check all that apply)	
<input type="checkbox"/> death (mo/day/yr)	<input type="checkbox"/> disability
<input type="checkbox"/> life-threatening	<input type="checkbox"/> congenital anomaly
<input checked="" type="checkbox"/> hospitalization - initial or prolonged	<input type="checkbox"/> required intervention to prevent permanent impairment/damage
	<input type="checkbox"/> other
3. Date of event (mo/day/yr) <u>2/25/98</u>	4. Date of this report (mo/day/yr) <u>5/15/98</u>

5. Describe event or problem

Patient had started on "Ephedria"
Herbal weight loss product
about 1 week prior to admission.
Pt experienced loss of
consciousness & new seizure
onset (no previous history of
seizure activity)

6. Relevant tests/laboratory data, including dates

All WNL REC'D.
MAY 27 1998
MEDWATCH CTU

7. Other relevant history, including preexisting medical conditions (e.g., allergies, race, pregnancy, smoking and alcohol use, hepatic/renal dysfunction, etc.)

NKA, no ~~previous~~ Depression

C. Suspect medication(s)

1. Name (give labeled strength & mfr/labeler, if known)	
#1 <u>"Ephedria"</u>	
#2	
2. Dose, frequency & route used	
#1 <u>unknown</u>	
#2	
3. Therapy dates (if unknown, give duration from/to (or best estimate))	
#1 <u>2/18 - 2/25</u>	
#2	
4. Diagnosis for use (indication)	
#1 <u>weight loss</u>	
#2	
5. Event abated after use stopped or dose reduced	
#1 <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply	
#2 <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply	
6. Lot # (if known)	
#1 <u>unknown</u>	
#2	
7. Exp. date (if known)	
#1	
#2	
8. Event reappeared after reintroduction	
#1 <input type="checkbox"/> yes <input type="checkbox"/> no <input checked="" type="checkbox"/> doesn't apply	
#2 <input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> doesn't apply	
9. NDC # (for product problems only)	
#1	
#2	
10. Concomitant medical products and therapy dates (exclude treatment of event)	
<u>Paxil</u>	

D. Suspect medical device

1. Brand name	
2. Type of device	
3. Manufacturer name & address	
4. Operator of device	
<input type="checkbox"/> health professional <input type="checkbox"/> lay user/patient <input type="checkbox"/> other	
5. Expiration date (mo/day/yr)	
6. model #	
catalog #	
serial #	
lot #	
other #	
7. If implanted, give date (mo/day/yr)	
8. If explanted, give date (mo/day/yr)	
9. Device available for evaluation? (Do not send to FDA)	
<input type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> returned to manufacturer on (mo/day/yr)	
10. Concomitant medical products and therapy dates (exclude treatment of event)	

000001

E. Reporter (see confidentiality section on back)

2. Health professional? <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	3. Occupation <u>Pharmacist</u>	4. Also reported to
5. If you do NOT want your identity disclosed to the manufacturer, place an "X" in this box. <input type="checkbox"/>		<input type="checkbox"/> manufacturer <input type="checkbox"/> user facility <input type="checkbox"/> distributor



Mail to: MEDWATCH
5600 Fishers Lane
Rockville, MD 20852-9787
or FAX to:
1-800-FDA-0178

ADVICE ABOUT VOLUNTARY REPORTING

Report experiences with:

- medications (drugs or biologics)
- medical devices (including in-vitro diagnostics)
- special nutritional products (dietary supplements, medical foods, infant formulas)
- other products regulated by FDA

Report **SERIOUS** adverse events. An event is serious when the patient outcome is:

- death
- life-threatening (real risk of dying)
- hospitalization (initial or prolonged)
- disability (significant, persistent or permanent)
- congenital anomaly
- required intervention to prevent permanent impairment or damage

Report even if:

- you're not certain the product caused the event
- you don't have all the details

Report product problems – quality, performance or safety concerns such as:

- suspected contamination
- questionable stability
- defective components
- poor packaging or labeling

How to report:

- just fill in the sections that apply to your report
- use section C for all products except medical devices
- attach additional blank pages if needed
- use a separate form for each patient
- report either to FDA or the manufacturer (or both)

Important numbers:

- 1-800-FDA-0178 to FAX report
- 1-800-FDA-7737 to report by modem
- 1-800-FDA-1088 for more information or to report quality problems
- 1-800-822-7967 for a VAERS form for vaccines

If your report involves a serious adverse event with a device and it occurred in a facility outside a doctor's office, that facility may be legally required to report to FDA and/or the manufacturer. Please notify the person in that facility who would handle such reporting.

Confidentiality: The patient's identity is held in strict confidence by FDA and protected to the fullest extent of the law. The reporter's identity may be shared with the manufacturer unless requested otherwise. However, FDA will not disclose the reporter's identity in response to a request from the public, pursuant to the Freedom of Information Act.

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send your comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Reports Clearance Officer, PHS
Hubert H. Humphrey Building,
Room 721-B
200 Independence Avenue, S.W.
Washington, DC 20201
ATTN: PRA

and to:
Office of Management and
Budget
Paperwork Reduction Project
(0910-0230)
Washington, DC 20503

Please do NOT
return this form
to either of these
addresses.

FDA Form 3500-back

Please Use Address Provided Below – Just Fold In Thirds, Tape and Mail

Department of Health and Human Services

Public Health Service
Food and Drug Administration
Rockville, MD 20857

Official Business

Penalty for Private Use \$300

BUSINESS REPLY MAIL

FIRST CLASS MAIL PERMIT NO. 946 ROCKVILLE, MD

POSTAGE WILL BE PAID BY FOOD AND DRUG ADMINISTRATION

MEDWATCH

The FDA Medical Products Reporting Program
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20852-9787

52-84 6-NOV 86

RECEIVED
CLINICAL RESEARCH
& REVIEW/OSN HFS-452



NO POSTAGE
NECESSARY
IF MAILED
IN THE
UNITED STATES
OR APO/FPO

000002



DEPARTMENT OF HEALTH AND HUMAN SERVICE

Public Health Service

Food and Drug Administration
Detroit District Office
Central Region
1560 East Jefferson Avenue
Detroit, MI 48207-3179
Telephone: (313) 226-6260
FAX: (313) 226-3076

To: ~~George M. Wallace/ ARMS Monitor, CFSAN/ HFS-636~~
Through Dennis R. Downer, SCSO [REDACTED] DET-DO *GRD*
From: George G. Calafactor, CSO, [REDACTED] DET-DO
Subj.: Adverse Event Project # 12927
Date: February 16, 1999




On 1/29/99, [REDACTED] received via fax from DET-DO, the 8/6/98 CFSAN request for follow-up on Adverse Event Report # 12927 (Ephedria herbal weight loss product). The assignment asks to follow-up on MEDWATCH complaint # 83864. - [REDACTED] is the MEDWATCH reporter.

This assignment had been inadvertently lost in DET-DO.

From 2/1-4/99, I attempted to contact Ms [REDACTED] via telephone @ [REDACTED]. On 2/4/99, I finally reached Ms [REDACTED]. I explained to her the assignment, apologizing about the follow-up delay. Since the complaint was about 1 year old, she would have to check the hospital records. However, per hospital policy, she explained that she was not allowed to supply me with the name/ address/ telephone # of the complainant until she has permission from the complainant. I informed her to contact the complainant then follow-up with me.

Since I have not heard back from Ms [REDACTED] I re-telephoned her on 2/10/99. She stated that she tried to reach the complainant; however, her telephone number had been disconnected. She assumes that the complainant had moved from the [REDACTED] area. She has no forwarding address/ telephone number for the complainant.

Since Ms [REDACTED] was not able to contact the complainant, the CFSAN assignment could not be completed.


George G. Calafactor, CSO
[REDACTED]
Detroit District

cc : DET-DO COMPLAINT FILES
[REDACTED] COMPLAINT FILES

000003